GoAI
Get started
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc.

ANIK

NASDAQHealthcareMedical - Specialties

Open in GoAI

Previous close

$21.78

+$0.44 · +2.06%

Aug 21, 4:00 PM ET

ANIK company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

48

Fair Value

Momentum

57

Neutral

Sentiment

66

Bullish

Risk resilience

74

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
US
CEO
Stephen D. Griffin
Listed since
May 3, 1993
Employees
235

Market position

Day range

Current $21.78

52-week range

Current $21.78

Open
$21.38
Previous close
$21.34
Volume
340.43K
3.52× average
Average volume
96.58K
Average daily volume
Market cap
291.48M USD
Beta
0.19
Market reference 1
50-day average
$17.0466
+27.77% above average
200-day average
$13.3812
+62.77% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-80.82×
P/B (TTM)
2.13×
P/S (TTM)
2.42×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.16%
Operating margin
-4.24%
Net margin
-3.14%

Financial health

Debt / equity
0.17×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends82%27%-27%-82%Gross margin, FY2021: 56.12%Gross margin, FY2022: 64.33%Gross margin, FY2023: 68.33%Gross margin, FY2024: 63.38%Gross margin, FY2025: 56.56%Operating margin, FY2021: 1.77%Operating margin, FY2022: 3.22%Operating margin, FY2023: 0.70%Operating margin, FY2024: -4.25%Operating margin, FY2025: -9.80%Net margin, FY2021: 2.80%Net margin, FY2022: -13.05%Net margin, FY2023: -68.44%Net margin, FY2024: -47.02%Net margin, FY2025: -9.64%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 56.12%. Gross margin FY2022 64.33%. Gross margin FY2023 68.33%. Gross margin FY2024 63.38%. Gross margin FY2025 56.56%. Operating margin FY2021 1.77%. Operating margin FY2022 3.22%. Operating margin FY2023 0.70%. Operating margin FY2024 -4.25%. Operating margin FY2025 -9.80%. Net margin FY2021 2.80%. Net margin FY2022 -13.05%. Net margin FY2023 -68.44%. Net margin FY2024 -47.02%. Net margin FY2025 -9.64%.

Income trends

Revenue

112.82M USD-5.91%

Operating income

−11.05M USD-116.64%

Net income

−10.88M USD+80.70%
Income trends across reported periods170.84M USD78.66M USD−13.53M USD−105.71M USDRevenue, FY2021: 147.79M USDRevenue, FY2022: 113.83M USDRevenue, FY2023: 120.79M USDRevenue, FY2024: 119.91M USDRevenue, FY2025: 112.82M USDOperating income, FY2021: 2.62M USDOperating income, FY2022: 3.67M USDOperating income, FY2023: 844K USDOperating income, FY2024: −5.1M USDOperating income, FY2025: −11.05M USDNet income, FY2021: 4.13M USDNet income, FY2022: −14.86M USDNet income, FY2023: −82.67M USDNet income, FY2024: −56.39M USDNet income, FY2025: −10.88M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 147.79M USD. Revenue FY2022 113.83M USD. Revenue FY2023 120.79M USD. Revenue FY2024 119.91M USD. Revenue FY2025 112.82M USD. Operating income FY2021 2.62M USD. Operating income FY2022 3.67M USD. Operating income FY2023 844K USD. Operating income FY2024 −5.1M USD. Operating income FY2025 −11.05M USD. Net income FY2021 4.13M USD. Net income FY2022 −14.86M USD. Net income FY2023 −82.67M USD. Net income FY2024 −56.39M USD. Net income FY2025 −10.88M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue112.82M USD119.91M USD120.79M USD113.83M USD147.79M USD
Cost of goods sold49.01M USD43.91M USD38.26M USD40.61M USD64.85M USD
Gross profit63.81M USD76M USD82.53M USD73.22M USD82.94M USD
Research and development25.77M USD25.54M USD21.76M USD18.32M USD27.33M USD
Selling, general, and administrative49.09M USD55.56M USD59.93M USD51.23M USD74.1M USD
Operating expenses74.86M USD81.1M USD81.69M USD69.55M USD80.33M USD
Interest income——2.31M USD654K USD—
Depreciation and amortization5.73M USD8.12M USD14.22M USD14.49M USD14.32M USD
Operating income−11.05M USD−5.1M USD844K USD3.67M USD2.62M USD
Net income−10.88M USD−56.39M USD−82.67M USD−14.86M USD4.13M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 6 misses, 1 met estimate
Average EPS surprise
+3.69%
11 comparable reports
Latest EPS result
0.42
Estimate 0.03 · Beat by 1300.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.460.250.04-0.17Q1 '25MissQ2 '25MissQ3 '25MetQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual -0.03, estimate -0.01, surprise -200.00%, Miss. Q2 2025, reported May 9, 2025: actual -0.06, estimate 0.09, surprise -166.67%, Miss. Q3 2025, reported Jul 30, 2025: actual -0.13, estimate -0.13, surprise 0.00%, Met estimate. Q4 2025, reported Nov 5, 2025: actual 0.04, estimate 0.02, surprise +100.00%, Beat. Q1 2026, reported Feb 26, 2026: actual 0.31, estimate -0.125, surprise +348.00%, Beat. Q2 2026, reported Apr 29, 2026: actual 0.27, estimate -0.07, surprise +485.71%, Beat. Q3 2026, reported Jul 29, 2026: actual 0.42, estimate 0.03, surprise +1300.00%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.235, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates35.32M22.21M9.11M-4MQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual -1.29M USD, estimate 28.13M USD, surprise -104.59%, Miss. Q2 2025, reported May 9, 2025: actual 26.17M USD, estimate 28.07M USD, surprise -6.76%, Miss. Q3 2025, reported Jul 30, 2025: actual 28.22M USD, estimate 27.53M USD, surprise +2.49%, Beat. Q4 2025, reported Nov 5, 2025: actual 27.82M USD, estimate 27.8M USD, surprise +0.06%, Beat. Q1 2026, reported Feb 26, 2026: actual 30.62M USD, estimate 28.88M USD, surprise +6.03%, Beat. Q2 2026, reported Apr 29, 2026: actual 29.61M USD, estimate 28.14M USD, surprise +5.22%, Beat. Q3 2026, reported Jul 29, 2026: actual 32.61M USD, estimate 29.21M USD, surprise +11.62%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 29.74M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$21.00

3.58% downside
Past 12 months12-month forecastHigh $21.00Average $21.00Low $21.00

Rating distribution

7 ratings
Strong buy00%
Buy457%
Hold343%
Sell00%
Strong sell00%

ANIK peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ANIK

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
7.67M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
6.54M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.01M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.22M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.44M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Dimensional - US Small Cap Value ETF logoDimensional - US Small Cap Value ETFDFSV
Market value
1.28M
Weight
0.02%
AUM
8.42B USD
Expense ratio
0.30%
Price / 1D
$40.29+0.72%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.24M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
1.05M
Weight
0.01%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%

Continue in GoAI

Research ANIK

research.disclaimer